Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

APPY 0.560 -0.004 (-0.64%)
price chart
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced by ...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of purchasers of the securities of Venaxis, Inc. (�Venaxis� or the �Company�) (NASDAQ:APPY ...
Analyst Rating Update on Venaxis, Inc.
Canaccord Genuity downgrades their rating on the shares of Venaxis, Inc. (NASDAQ:APPY). The current rating of the shares is Hold.
Venaxis, Inc. to Present at Biotech Showcase� 2015
6, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young ...
Related articles »  
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces ...
NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company") (NasdaqCM: APPY -News).
Venaxis, Inc. Price Target Update
Venaxis, Inc. (NASDAQ:APPY): 1 Analyst have given the stock of Venaxis, Inc. (NASDAQ:APPY) a near short term price target of $0.5.
NASDAQ:APPY Investor filed Lawsuit over alleged Securities Laws Violations ...  Empowered News
Volatile Stocks: Venaxis Inc , Lexington Realty Trust , Zimmer Holdings Inc  Winston View
Weakening Healthcare Stocks for Week: Celsus Therapeutics (NASDAQ:CLTX ...
Venaxis Inc (NASDAQ:APPY), traded on a volume of 1.27M, higher than its standard daily volume. Shares have gained 2.78% to $0.555.
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  PR Newswire (press release)
Related articles »  
INVESTOR ALERT: Investigation of Venaxis, Inc. Announced by Glancy Binkow ...
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. (�Venaxis� or the �Company�) (APPY) concerning possible violations of federal securities laws. The investigation is focused on ...
Venaxis' appendicitis test not found equivalent to standard care
Jan 29 (Reuters) - Venaxis Inc said its appendicitis test was not found to be substantially equivalent to standard of care by the U.S.
Morning Market Losers  Benzinga
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  MarketWatch